by Ramon De La Puerta (Z-Lounge Regenerative Medicine and Stem Cell Therapy Centers)
Lyme disease can leave patients suffering long after a tick bite, but an emerging therapy offers fresh hope. Umbilical cord-derived mesenchymal stem cells (MSCs) — special cells from newborns’ umbilical cords — are being explored as a revolutionary treatment for chronic Lyme symptoms. Early evidence and patient stories suggest these stem cells may reduce persistent inflammation and restore quality of life when antibiotics fall short. This article explores how MSC therapy works, the latest clinical insights (as of 2024–2025), and what patients should know about accessing this potential breakthrough.
The Challenge of Chronic Lyme Disease
Lyme disease is a bacterial infection transmitted by tick bites, infamous for causing fever, rash, and joint pain in its early stages. Prompt antibiotic treatment can usually cure acute Lyme. However, a significant minority (around 10–20%) of patients continue to experience debilitating symptoms for months or even years after standard treatment. This condition is often called chronic Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS). Sufferers may endure fatigue, muscle and nerve pain, cognitive fog, and even arthritis or neurological issues long after the infection is supposedly cleared.
Why is chronic Lyme so hard to treat? Researchers are still unraveling it. One theory is that remnants of the bacteria or immune system overreactions trigger ongoing inflammation. Another challenge is that Lyme symptoms overlap with other conditions, making diagnosis and treatment tricky. What’s clear is that standard antibiotics often don’t repair the damage or end the inflammation once Lyme becomes chronic. Patients can feel stuck — having tried medications, supplements, and lifestyle changes — yet still not be back to normal health. With hundreds of thousands of new Lyme cases each year in North America, the number of people struggling with long-term symptoms is substantial. This has driven interest in innovative therapies like stem cells that might do what antibiotics can’t — reset the immune system, repair tissue, and finally bring relief.
Mesenchymal Stem Cells: How They Work
Mesenchymal stem cells (MSCs) are a type of adult stem cell known for their remarkable healing abilities. They can be obtained from various tissues (bone marrow or fat), but one especially potent source is umbilical cord tissue donated after healthy births. Umbilical cord-derived MSCs are young, vibrant cells that have not been exposed to aging or disease, and collecting them poses no risk or ethical controversy (unlike embryonic stem cells) because they come from medical waste (the post-birth cord).
Once isolated and multiplied in a lab, MSCs act as the body’s “repairmen” and modulators. They don’t typically turn into new liver or brain cells inside you; instead, they work by sending out signals (cytokines and growth factors) that encourage damaged tissues to heal and calm down overactive immune responses. In Lyme disease, where persistent inflammation and immune dysfunction are thought to cause symptoms, MSCs could play a crucial role in dialing back the immune system’s overreaction. These cells interact with T cells, B cells, natural killer cells, and more, effectively rebalancing immune responses that might be misfiring in chronic Lyme. MSCs also release anti-inflammatory substances and promote the formation of new blood vessels and tissue repair, potentially helping to regenerate areas harmed by the infection.
Another advantage of umbilical cord MSCs is that they are immune-privileged — the body’s defenses don’t readily recognize them as foreign. This means a patient can receive MSCs from a donor’s cord without needing risky tissue matching or anti-rejection drugs. Clinics have treated thousands of patients with umbilical cord MSC infusions without any cases of rejection. The procedure is typically as simple as an intravenous (IV) infusion over an hour or so. Most patients tolerate it well, experiencing at most mild side effects like a fever or headache for a day or two, if any.
Early Evidence: Can Stem Cells Help Lyme Patients?
MSC therapy for Lyme is still new and experimental, but a growing number of studies and patient anecdotes are fueling optimism. Here are some of the most noteworthy findings and expert observations to date:
- Case Reports of Recovery: In 2018, Dr. Richard Horowitz — a prominent Lyme specialist — published the first case report of a Lyme disease patient improving with stem cell therapy. The patient had a complicated case of Lyme along with an immune deficiency. After receiving human embryonic stem cell treatments, her energy and immune markers rebounded, indicating improvement in Lyme symptoms and the immune disorder.
This pioneering report suggested that stem cells could address the underlying immune dysfunction seen in chronic Lyme.
- Brain Imaging Study: A clinical study of 59 patients in India looked at brain scans (SPECT imaging) before and after stem cell therapy for Lyme. The results were striking — after treatment with human embryonic stem cells, 73% of patients showed significant (>60%) improvement in brain perfusion (blood flow), and most of the rest showed moderate improvements. Many chronic Lyme patients suffer cognitive problems or “Lyme brain,” often linked to impaired blood flow or inflammation in the brain. This study concluded that stem cell therapy markedly improved objective brain function measures, offering visual evidence that it benefits the central nervous system. (Note: This study used embryonic stem cells; today, many clinics favor umbilical cord MSCs due to fewer ethical issues and easier availability, but both cell types share anti-inflammatory properties.)
- Patient Testimonials & Case Series: Outside of formal trials, Lyme patients themselves have reported notable recoveries after MSC therapy. For example, at an offshore stem cell clinic in Grand Cayman, a young man with chronic Lyme saw his constant joint pain vanish within a day of treatment. Over the following months, his neurological symptoms and even unrelated issues (like an esophagus condition) dramatically improved. After one year, his Lyme symptoms were gone entirely, astonishing his physicians. While this is just one anecdote, it reflects a trend seen by some physicians: patients who felt “stuck” in a cycle of Lyme flares experienced what can only be described as a life-changing turnaround following stem cell therapy. Another stem cell clinic reported preliminary data that about 85% of their Lyme patients experience symptom improvements within 3 months of umbilical cord MSC infusions. Although not yet confirmed by large-scale trials, such accounts hint at the tangible improvements in energy, pain levels, and cognitive function stem cells may provide.
- Expert Opinions: Neil Riordan, PA, Ph.D. — Founder of the Stem Cell Institute in Panama and a leading figure in stem cell therapy — has noted that direct research on Lyme-specific stem cell treatment is limited, but he draws parallels to autoimmune diseases. Lyme, especially in its chronic form, can trigger autoimmune-like problems, and MSCs have been successfully used against autoimmune conditions like rheumatoid arthritis (RA) and multiple sclerosis (MS). Riordan’s clinic uses umbilical cord MSCs and has treated several patients suffering long-term Lyme symptoms (often alongside another autoimmune disorder) with encouraging results. He emphasizes that the way Lyme affects the body — causing systemic inflammation and immune dysregulation — makes it a logical candidate for MSC therapy, even if formal Lyme protocols are still in development. In essence, some Lyme specialists and regenerative medicine experts see stem cells as a way to “reset” an overwhelmed immune system and repair collateral damage from the infection.
Despite these positive signs, it’s important to stress that no one is calling MSC therapy a proven cure for Lyme disease. The experiences above, while hopeful, come from early-stage research, individual cases, and clinical observations. Rigorous clinical trials are needed to confirm efficacy and safety for Lyme patients. Fortunately, interest in this therapy is rising, and more studies are expected in the next few years. Already, MSCs have shown benefits in conditions as diverse as acute respiratory distress syndrome (ARDS) and kidney injury by tamping down excessive inflammation– a mechanism very relevant to Lyme. The Lyme community is watching closely to see if science will back up what some patients and doctors suspect: stem cells could be a game-changer for chronic Lyme disease.
Potential Benefits of MSC Therapy for Lyme
Given what we know, why are Lyme patients excited about umbilical cord MSC therapy? Here are some of the potential benefits in the context of chronic Lyme, explained in plain language:
- Immune System Modulation: Chronic Lyme involves a misfiring immune response (the body might be attacking residual bacteria or even its own tissues). MSCs act as immune system balancers. They release factors that reduce inflammation and autoimmunity, potentially easing symptoms like joint pain, swelling, and neuroinflammation. In other diseases, MSC infusions have lowered harmful inflammation, so the hope is they can recalibrate an overstimulated immune system in Lyme patients as well.
- Tissue Repair and Regeneration: Lyme can damage various tissues, for instance, causing nerve damage (neuropathy) or arthritis in joints. MSCs can differentiate into multiple cell types and secrete growth factors, which may support the repair of damaged muscles, nerves, and cartilage. For example, patients with long-term Lyme often have lingering arthritis; an MSC therapy could aid in regenerating cartilage and reducing inflammation in affected joints. Similarly, some Lyme patients experience brain fog due to neural damage; MSCs might help by promoting neuronal healing or improved blood flow (as seen in the SPECT scan study).
- Symptom Relief: The most compelling (and immediate) benefit reported is broad symptom relief. Fatigue, one of Lyme’s most crushing symptoms, has improved in patients after MSC therapy — some report feeling energetic for the first time in years. Chronic pain levels may drop as inflammation subsides. Cognitive clarity and mood can also get better, according to anecdotal reports. It’s important to note these are subjective improvements from early reports; controlled trials are needed to verify them. However, even anecdotal success stories offer a light at the end of the tunnel for patients.
- Low Risk of Rejection: Unlike organ transplants, allogeneic (donor) MSC therapy does not require immune matching. The cells from donated umbilical cords are universally tolerated in the body. This means treatment is relatively simple — no need to harvest the patient’s cells (which might be less potent or available), and no intense immune suppression. The safety profile so far appears favorable: thousands of patients have been treated with cord-derived MSCs in studies for various conditions with few serious adverse events. Most side effects are minor or transient, like headaches or low-grade fevers. This makes stem cell therapy, at least in regulated settings, generally considered safe.
- Long-Term Healing vs. Short-Term Drugs: A hope with stem cells is that they could provide a more lasting solution. Antibiotics, while initially critical to kill the Lyme bacteria, don’t always fix the immune aftermath. They also come with side effects when used long-term. MSC therapy, in contrast, may offer sustained improvements by addressing the root causes of ongoing symptoms (like immune imbalance and tissue damage) rather than repeatedly targeting bacteria with diminishing returns. Some patients view it as a way to potentially reduce reliance on medications in the long run if it leads to remission of symptoms.
Of course, with potential benefits come potential risks and uncertainties, which we’ll address next.
Risks and Unknowns to Consider
As exciting as MSC therapy sounds, it’s essential to approach it with realistic caution. Here are some potential risks or downsides Lyme patients should weigh:
- Experimental Status: MSC therapy for Lyme is not yet an established, FDA-approved treatment. It’s considered experimental, which means we lack large, definitive clinical trials proving it works. Any patient pursuing this therapy is essentially forging into somewhat uncharted territory. Results can vary widely — one person might feel 90% better, while another sees minimal change. Until more research is done, there’s an uncertainty factor.
- Unknown Long-Term Effects: Because this therapy is relatively new, scientists are still studying its long-term safety. Will the improvements last for years? Could there be delayed side effects? We don’t have decades-long data yet. So far, no serious long-term complications have emerged in MSC trials, but careful follow-up is ongoing. Some experts voice concerns that, theoretically, infused stem cells could trigger unwanted immune reactions or growth of tissues in the wrong place. However, no such issues have been documented in clinical use to date.
- Cost and Access: Stem cell treatments can be expensive, often costing thousands to tens of thousands of dollars per round of therapy. Insurance typically does not cover experimental treatments like this. Patients must often pay out-of-pocket or seek funding for therapy and related travel expenses. Moreover, access is limited to certain clinics or trial sites. MSC therapy is not easily obtainable for everyone; it might require traveling to specialized centers (sometimes in other countries), which can be a practical and financial hurdle.
- Regulatory and Quality Concerns: Regulators have strict rules for stem cell treatments in the U.S. and Canada. As of now, no stem cell therapy is officially approved for Lyme or PTLDS, and authorities have been cracking down on clinics that market unproven cures. The FDA, for instance, has warned clinics (like the R3 Stem Cell company in Arizona) against advertising unapproved stem cell products for Lyme disease and other conditions. Health Canada has issued advisories and shut down numerous private clinics offering unlicensed stem cell therapies in recent years. This doesn’t mean the therapy is dangerous — it means you should be careful to seek out legitimate, reputable providers if you pursue it. Patients should do thorough research and consult medical professionals, because the field has attracted some “cowboy” clinics. The good news is that credible treatment centers exist (more on this below in Access).
- Not a Guaranteed Cure: Finally, it must be emphasized: stem cell therapy is not a magic bullet. While it can sound almost miraculous in some success stories, other patients may see only modest improvement, and a few might not feel much better. Chronic Lyme is a complex illness; stem cells address one big piece (inflammation/immune dysfunction), but there might be other issues to tackle (like co-infections or lingering bacterial forms). To truly heal, some patients might need combination approaches — e.g., stem cells, antibiotics, and rehabilitation. Managing expectations is essential. As one Lyme specialist said, stem cells are “an emerging treatment for Lyme disease and more research is needed to fully understand its potential benefits and risks”. It’s wise for patients to remain hopeful but also informed and cautious.
In summary, the risk profile of umbilical cord MSC therapy appears relatively low in terms of immediate side effects. Still, the main cautions concern uncertainties and ensuring you get treatment from a trustworthy source.
Accessing Stem Cell Therapy in the U.S. and Canada
If you’re a Lyme patient in the U.S. or Canada interested in MSC therapy, navigating access can be confusing. Here’s what you need to know about the current regulatory and practical landscape:
- United States: In the U.S., the FDA treats any stem cell product that is more than “minimally manipulated” (which includes expanded MSCs from umbilical cords) as a drug. That means it must undergo clinical trial testing and FDA approval before being marketed. So far, no such product is approved for Lyme disease or related conditions. As a result, you generally cannot go to your local hospital or doctor and get an MSC infusion for Lyme as a standard treatment. The options in the U.S. are usually: (1) Enroll in a clinical trial if one is available (as of 2025, few if any trials are directly focused on Lyme and MSCs, but this could change), or (2) Visit a specialty clinic offering cell therapy under research protocols or “patient-funded studies.” Some clinics operate under regulatory loopholes or under the FDA’s enforcement discretion for experimental therapies, but patients should be very cautious. The FDA has issued warnings to clinics making unfounded claims. If considering U.S. options, look for those affiliated with reputable research institutions or those listed on clinicaltrials.gov, and always discuss with your healthcare provider.
- Canada: Health Canada views unapproved stem cell treatments similarly — they are not authorized outside clinical trials. Canada has recently become even more strict: in 2019, Health Canada sent cease and desist letters to 36 clinics advertising unproven stem cell therapies. The result is that very few clinics in Canada now openly offer MSC therapy for Lyme or anything else. Besides possibly enrolling in a research study, Canadian patients likely will not find legal stem cell treatment for Lyme domestically. The practical route for Canadians is often to look abroad or across the border, albeit with careful consideration of quality and legality.
- International and Offshore Clinics: Many Lyme sufferers turn to international stem cell clinics that have sprung up in countries with more flexible regulations. Popular destinations include Panama, Mexico, the Cayman Islands, and some parts of Europe (e.g., Germany). For instance, the Stem Cell Institute in Panama (founded by Neil Riordan) has treated patients from the U.S. and Canada for years, using umbilical cord MSCs under Panama’s regulatory oversight.
These clinics often cater to international patients and may have physicians experienced in Lyme and other chronic illnesses. However, quality varies—it’s crucial to choose clinics with proper licensing, sterile laboratory practices, and experienced medical staff.
- Clinical Trials and Studies: As of early 2025, formal clinical trials testing MSC therapy for chronic Lyme are limited. Patients can keep an eye on clinical trial registries for any new studies. Sometimes, trials for related conditions (like post-COVID inflammatory syndromes or arthritis) might consider participants with a Lyme history, given similar inflammatory pathways.
- Practical Preparation: If you pursue stem cell therapy, prepare thoroughly. Consult your Lyme-treating physician to discuss any risks given your personal medical history. Gather your medical records, test results, and treatment history — reputable clinics will want to review these to ensure you’re a suitable candidate. Ask questions about the source of the MSCs, about the treatment protocol (How many cells? IV only or any other delivery? One-time or multiple rounds?), and about follow-up care (Will the clinic work with your doctor for aftercare, what symptoms to watch for, etc.). Also inquire about total costs, travel logistics, and time required on-site. Many clinics offer packages that include hotel, transportation, etc., especially those geared to medical tourism. For example, Z-Lounge Regenerative Medicine in Cancun, Mexico, coordinates airport pickup and hotel stays for a seamless experience. While these details don’t reflect the therapy’s medical efficacy, they matter for comfort and planning.
In short, accessing MSC therapy as a Lyme patient typically means stepping outside the conventional medical system — either by joining a trial or by traveling to a specialized center. The U.S. and Canada have strict regulations to protect patients, so doing homework to find safe and ethical treatment providers is essential. Do not trust “too good to be true” cures you might stumble on online or in late-night ads. But do take heart that legitimate avenues are available and expanding as the therapy gains recognition.
Conclusion: A Cautiously Optimistic Outlook
For those grappling with the physical and emotional toll of chronic Lyme disease, umbilical cord stem cell therapy represents a beacon of hope on the horizon. This cutting-edge treatment aims to do what traditional antibiotics cannot — heal the damage and calm the chronic inflammation left in Lyme’s wake. We’ve seen that early patient experiences and preliminary studies are promising, with reports of improved energy, reduced pain, better brain function, and even cases of long-term remission. Experts in regenerative medicine believe MSCs could “reset” the immune system and promote recovery in a way no drug currently can.
Yet, as of 2025, this therapy is still finding its footing in the medical world. It’s not a silver bullet or guaranteed cure and is not widely accessible as a standard treatment. Patients and caregivers should stay informed: follow new research updates, consult knowledgeable doctors, and approach any treatment decision carefully. If you decide to pursue stem cell therapy, do so with realistic expectations and through reputable channels — your safety comes first.
The story of Lyme disease has long been one of perseverance against a stubborn foe. With the advent of mesenchymal stem cell therapy, we may be turning a page toward more effective management of chronic Lyme. Many in the Lyme community are cautiously optimistic that in the next few years, ongoing clinical trials and accumulating patient outcomes will clarify the actual impact of MSCs. Could this be the breakthrough that finally ends the suffering for countless Lyme warriors? Time and science will tell. For now, umbilical cord stem cell therapy offers hope — a sign that innovative solutions are coming for those who have endured Lyme’s long storm.
Let’s Stay Connected!
If you found this article helpful and want to learn more about regenerative medicine, stem cell therapy, and biohacking for longevity, follow me across platforms:
Website: www.zlounge.com.mx
Instagram: https://tinyurl.com/Z-Lounge-IG
Facebook: https://tinyurl.com/Z-Lounge-FB
YouTube: https://tinyurl.com/Z-Lounge-YT
LinkedIn: https://tinyurl.com/Z-Lounge-Linkedin
Subscribe on Medium to get notified when I publish new content written to empower your health journey.
References
Horowitz, R. I., & Freeman, P. R. (2018). Improvement of common variable immunodeficiency using embryonic stem cell therapy in a patient with Lyme disease: A clinical case report. Clinical Case Reports, 6(6), 1166–1171. https://doi.org/10.1002/ccr3.1556
Melia, M. T., & Berende, A. (2016). Time for a different approach to Lyme disease and long-term symptoms. New England Journal of Medicine, 374(13), 1277–1278. https://doi.org/10.1056/NEJMe1502350
Meyerhoff, J. D., & Diamond, H. S. (2019, November 12). Lyme disease treatment & management: Approach considerations, treatment of early Lyme disease, Lyme arthritis. Medscape. Retrieved from https://emedicine.medscape.com/article/330178-treatment
New York State Department of Health. (2019, May 24). Proper precautions can help prevent Lyme disease and the spread of tick-borne illnesses [Press release]. https://www.health.ny.gov/press/releases/2019/2019-05-24_lyme_and_ticks.htm
Shroff, G. (2016). Transplantation of human embryonic stem cells in patients with multiple sclerosis and Lyme disease. American Journal of Case Reports, 17, 944–949. https://doi.org/10.12659/AJCR.899745
U.S. Food and Drug Administration. (2019, May 30). FDA puts company on notice for marketing unapproved stem cell products for treating serious conditions [Press release]. https://www.fda.gov/news-events/press-announcements/fda-puts-company-notice-marketing-unapproved-stem-cell-products-treating-serious-conditions
Wolf, A. B., Money, K. M., Chandnani, A., Daley, C. L., Griffith, D. E., Chauhan, L., Coffman, N., Piquet, A. L., Tyler, K. L., Zimmer, S. M., Montague, B. T., Mann, S., & Pastula, D. M. (2023). Mycobacterium abscessus meningitis associated with stem cell treatment during medical tourism. Emerging Infectious Diseases, 29(8), 1655–1658. https://doi.org/10.3201/eid2908.230317